Fluvoxamine
- Generic Name
- Fluvoxamine
- Brand Names
- Luvox
- Drug Type
- Small Molecule
- Chemical Formula
- C15H21F3N2O2
- CAS Number
- 54739-18-3
- Unique Ingredient Identifier
- O4L1XPO44W
- Background
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
...
- Indication
Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) . Has also been used in the management of bulimia nervosa .
- Associated Conditions
- Bulimia Nervosa, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Fluvoxamine for Adults With Mild to Moderate COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT04711863
- Locations
- ๐ฐ๐ท
Asan Medical Center, Seoul, Korea, Republic of
Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 670
- Registration Number
- NCT04668950
- Locations
- ๐จ๐ฆ
McGill University Health Center, Montreal, Quebec, Canada
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
Pragmatic Trial of Obsessive-compulsive Disorder
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1600
- Registration Number
- NCT04539951
- Locations
- ๐จ๐ณ
Shanghai Mental Health Center, Shanghai, Shanghai, China
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 1323
- Registration Number
- NCT04510194
- Locations
- ๐บ๐ธ
Hennepin County Medical Center, Minneapolis, Minnesota, United States
๐บ๐ธUniversity of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธOlive View UCLA Medical Center, Sylmar, California, United States
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT04478513
- Locations
- ๐ฌ๐ง
Research Site, Harrow, United Kingdom
A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT04342663
- Locations
- ๐บ๐ธ
BJC, Belleville, Illinois, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
A Clinical Trial of Fluvoxamine for Melancholia
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Lingjiang Li
- Target Recruit Count
- 150
- Registration Number
- NCT04160377
- Locations
- ๐จ๐ณ
Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT03930602
- Locations
- ๐บ๐ธ
ICON Plc (PRA Health Sciences), Salt Lake City, Utah, United States
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-19
- Target Recruit Count
- 362
- Registration Number
- NCT03779789
- Locations
- ๐ฎ๐น
Azienda Ospedaliera Universitaria Mater Domini, Universitร Magna Grecia, Catanzaro, Italy
๐ฎ๐นSapienza Universitร di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
๐ฎ๐นAzienda Ospedaliera Universitaria Verona, Verona, Italy
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธAnn and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธLoma Linda University Health, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.